

105TH CONGRESS
1ST SESSION

H. R. 1398

To amend the Public Health Service Act to provide for the establishment of a program for research and training with respect to Parkinson's disease.

IN THE HOUSE OF REPRESENTATIVES

APRIL 17, 1997

Mr. SMITH of New Jersey (for himself, Mr. SAXTON, Mr. HAYWORTH, Mr. CUNNINGHAM, Mr. STEARNS, Mr. RAHALL, Mr. WELDON of Pennsylvania, Mr. WALSH, Mr. KING, Mr. LAFALCE, Mr. BUNNING, Mr. BOB SCHAFFER of Colorado, and Mr. NORWOOD) introduced the following bill; which was referred to the Committee on Commerce

A BILL

To amend the Public Health Service Act to provide for the establishment of a program for research and training with respect to Parkinson's disease.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the "Parkinson's Research
5 Act of 1997".

6 **SEC. 2. FINDING AND PURPOSE.**

7 (a) FINDING.—Congress finds that to take full ad-
8 vantage of the tremendous potential for finding a cure or

1 effective treatment for Parkinson’s disease, the Federal
2 investment in Parkinson’s must be expanded, as well as
3 the coordination strengthened among the National Insti-
4 tutes of Health research institutes.

5 (b) PURPOSE.—It is the purpose of this Act to pro-
6 vide for the expansion and coordination of research re-
7 garding Parkinson’s, and to improve care and assistance
8 for afflicted individuals and their family caregivers.

9 **SEC. 3. PARKINSON’S RESEARCH.**

10 Part B of title IV of the Public Health Service Act
11 (42 U.S.C. 284 et seq.) is amended by adding at the end
12 the following:

13 “PARKINSON’S DISEASE

14 “SEC. 409B. (a) IN GENERAL.—The Director of
15 NIH shall establish a program for the conduct and sup-
16 port of research and training with respect to Parkinson’s
17 disease (subject to the extent of amounts appropriated
18 under subsection (e)).

19 “(b) INTER-INSTITUTE COORDINATION.—

20 “(1) IN GENERAL.—The Director of NIH shall
21 provide for the coordination of the program estab-
22 lished under subsection (a) among all of the national
23 research institutes conducting Parkinson’s research.

24 “(2) CONFERENCE.—Coordination under para-
25 graph (1) shall include the convening of a research
26 planning conference not less frequently than once

1 every 2 years. Each such conference shall prepare
2 and submit to the Committee on Appropriations and
3 the Committee on Labor and Human Resources of
4 the Senate and the Committee on Appropriations
5 and the Committee on Commerce of the House of
6 Representatives a report concerning the conference.

7 “(c) MORRIS K. UDALL RESEARCH CENTERS.—

8 “(1) IN GENERAL.—The Director of NIH shall
9 award Core Center Grants to encourage the develop-
10 ment of innovative multidisciplinary research and
11 provide training concerning Parkinson’s. The Direc-
12 tor shall award not more than 10 Core Center
13 Grants and designate each center funded under such
14 grants as a Morris K. Udall Center for Research on
15 Parkinson’s Disease.

16 “(2) REQUIREMENTS.—

17 “(A) IN GENERAL.—With respect to Par-
18 kinson’s, each center assisted under this sub-
19 section shall—

20 “(i) use the facilities of a single insti-
21 tution or a consortium of cooperating insti-
22 tutions, and meet such qualifications as
23 may be prescribed by the Director of the
24 NIH; and

1 “(ii) conduct basic and clinical re-
2 search.

3 “(B) DISCRETIONARY REQUIREMENTS.—
4 With respect to Parkinson’s, each center as-
5 sisted under this subsection may—

6 “(i) conduct training programs for
7 scientists and health professionals;

8 “(ii) conduct programs to provide in-
9 formation and continuing education to
10 health professionals;

11 “(iii) conduct programs for the dis-
12 semination of information to the public;

13 “(iv) separately or in collaboration
14 with other centers, establish a nationwide
15 data system derived from patient popu-
16 lations with Parkinson’s, and where pos-
17 sible, comparing relevant data involving
18 general populations;

19 “(v) separately or in collaboration
20 with other centers, establish a Parkinson’s
21 Disease Information Clearinghouse to fa-
22 cilitate and enhance knowledge and under-
23 standing of Parkinson’s disease; and

24 “(vi) separately or in collaboration
25 with other centers, establish a national

1 education program that fosters a national
2 focus on Parkinson's and the care of those
3 with Parkinson's.

4 “(3) STIPENDS REGARDING TRAINING PRO-
5 GRAMS.—A center may use funds provided under
6 paragraph (1) to provide stipends for scientists and
7 health professionals enrolled in training programs
8 under paragraph (2)(B).

9 “(4) DURATION OF SUPPORT.—Support of a
10 center under this subsection may be for a period not
11 exceeding five years. Such period may be extended
12 by the Director of NIH for one or more additional
13 periods of not more than five years if the operations
14 of such center have been reviewed by an appropriate
15 technical and scientific peer review group established
16 by the Director and if such group has recommended
17 to the Director that such period should be extended.

18 “(d) MORRIS K. UDALL AWARDS FOR EXCELLENCE
19 IN PARKINSON'S DISEASE RESEARCH.—The Director of
20 NIH shall establish a grant program to support investiga-
21 tors with a proven record of excellence and innovation in
22 Parkinson's research and who demonstrate potential for
23 significant future breakthroughs in the understanding of
24 the pathogenesis, diagnosis, and treatment of Parkinson's.

1 Grants under this subsection shall be available for a period
2 of not to exceed 5 years.

3 “(e) AUTHORIZATION OF APPROPRIATIONS.—For the
4 purpose of carrying out this section, there are authorized
5 to be appropriated \$100,000,000 for fiscal year 1998, and
6 such sums as may be necessary for each of the fiscal years
7 1999 and 2000.

8 “(f) LIMITATION ON USE OF CERTAIN FUNDS OF
9 PUBLIC HEALTH SERVICE.—Notwithstanding any other
10 provision of law, none of the amounts made available
11 under this Act may be expended for any research that uses
12 human fetal tissue, cells, or organs obtained from a living
13 or dead human embryo or fetus during or after an induced
14 abortion, or for any therapeutic application for Parkin-
15 son’s that uses such human fetal tissue, cells, or organs.
16 This subsection does not apply to human fetal tissue, cells,
17 or organs obtained from a spontaneous abortion or an ee-
18 topic pregnancy.”.

○